Weight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized clinical trial

Simple item page
dc.contributor.authorOshakbayev, Kuat
dc.contributor.authorDukenbayeva, Bibazhar
dc.contributor.authorOtarbayev, Nurzhan
dc.contributor.authorTogizbayeva, Gulnar
dc.contributor.authorTabynbayev, Nariman
dc.contributor.authorGazaliyeva, Meruyert
dc.contributor.authorIdrisov, Alisher
dc.contributor.authorOshakbayev, Pernekul
dc.date.accessioned2017-11-22T06:25:30Z
dc.date.available2017-11-22T06:25:30Z
dc.date.issued2015-11-25
dc.description.abstractBackground: The prevalence and burden of atherosclerotic (AS) diseases are increasing during the last twenty years. Some studies show a close relationship between overweight and AS, but influence on AS diseases of different weight loss methods are still studying. The purpose of the research was to study the effectiveness of a weight loss program in AS patients in randomized controlled trial, and to develop a conception of evolution of AS. Methods: A randomized controlled prospective clinical trial including 97 people, from them 71 patients with various AS manifestations. Patients were divided in 2 subgroups for non-drug weight loss program, and conventional drug therapy. The weight loss program included calorie restriction with 100–150 kcal/day, fat-free vegetables, salt diet, and optimum physical activity. Statistical analysis was performed using SPSS for Windows version 17.0. Results: The weight loss subgroup lost ranging between 7-20 % from an initial weight (P = 0.016). Weight loss was achieved due to fatty mass reduction only (P = 0.005). Hemoglobin levels (P < 0.001), bone mineral density (P < 0.001), percentages of water (P = 0.006) and muscle masses (P = 0.0038) were increased in weight loss subgroup. Ejection fraction (P < 0.0001), systolic output (P < 0.0001) were increased in patients with coronary artery disease. The weight loss program led to a decrease in symptomatic drugs doses up to total abolition. A conception of AS was developed. Conclusions: The weight loss program treated the AS diseases; improved laboratory and instrumental parameters, decreased symptomatic drugs doses. AS development is a logical way of ontogenetic ageing of body fat.ru_RU
dc.identifier.citationOshakbayev Kuat et al.(>7), 2015(November 25), Weight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized clinical trial, Nutrition Journalru_RU
dc.identifier.uriDOI 10.1186/s12937-015-0108-y
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2843
dc.language.isoenru_RU
dc.publisherNutrition Journalru_RU
dc.rightsOpen Access - the content is available to the general publicru_RU
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectatherosclerosisru_RU
dc.subjectoverweightru_RU
dc.subjectweight lossru_RU
dc.subjectendogen metabolic intoxicationru_RU
dc.subjectageingru_RU
dc.subjectResearch Subject Categories::MEDICINEru_RU
dc.titleWeight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized clinical trialru_RU
dc.typeArticleru_RU

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Weight loss therapy for.pdf
Size:
867.52 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

UMC_Articles